A COST-EFFECTIVENESS ANALYSIS OF COMMONLY USED BIOLOGIC DRUGS FOR THE TREATMENT OF MODERATE-TO-SEVERE PSORIASIS IN THE UNITED STATES

被引：0
|
作者：
Wu, J. J. [1 ]
Feldman, S. R. [2 ]
Rastogi, S. [3 ]
Menges, B. [4 ]
Lingohr-Smith, M. [4 ]
Lin, J. [4 ]
机构：
[1] Kaiser Permanente Los Angeles Med Ctr, Los Angeles, CA USA
[2] Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA
[3] Ortho Dermatol, Bridgewater, NJ USA
[4] Novosys Hlth, Green Brook, NJ USA
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.04.1630
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSS8
引用
收藏
页码：S240 / S240
页数：1
相关论文
共 50 条
  • [1] Comparison of the cost-effectiveness of biologic drugs used for moderate-to-severe psoriasis treatment in the United States
    Wu, Jashin J.
    Feldman, Steven R.
    Rastogi, Shipra
    Menges, Brandy
    Lingohr-Smith, Melissa
    Lin, Jay
    [J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 2018, 29 (08) : 769 - 774
  • [2] Comparison of the cost-effectiveness of biologic drugs used for moderate-to-severe psoriasis treatment
    Wu, Jashin J.
    Rastogi, Shipra
    Menges, Brandy
    Lingohr-Smith, Melissa
    Lin, Jay
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB83 - AB83
  • [3] Cost-effectiveness of tildrakizumab for the treatment of moderate-to-severe psoriasis in the United States
    Jia, Xiaoying
    Zhao, Yang
    Carrico, Justin
    Brodtkorb, Thor-Henrik
    Mendelsohn, Alan M.
    Lowry, Simon
    Feldman, Steve
    Wu, Jashin J.
    Armstrong, April W.
    [J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (02) : 740 - 748
  • [4] Cost-effectiveness of treatment for moderate-to-severe psoriasis
    Hankin, CS
    Feldman, SR
    Pearce, D
    [J]. VALUE IN HEALTH, 2004, 7 (06) : 654 - 654
  • [5] Comparative cost-effectiveness of tildrakizumab and other commonly used treatments for moderate-to-severe psoriasis
    Wu, Jashin J.
    Jia, Xiaoying
    Zhao, Yang
    Carrico, Justin
    Brodtkorb, Thor-Henrik
    Mendelsohn, Alan
    Lowry, Simon
    Feldman, Steven R.
    Armstrong, April
    [J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 2021, 32 (07) : 693 - 700
  • [6] COST-EFFECTIVENESS ANALYSIS OF BIOLOGIC AGENTS IN THE TREATMENT OF MODERATE-TO-SEVERE PSORIASIS: A SYSTEMATIC LITERATURE REVIEW
    Sokolova, V
    Tolkacheva, D.
    [J]. VALUE IN HEALTH, 2019, 22 : S375 - S376
  • [7] COST-EFFECTIVENESS OF BIOLOGIC THERAPIES FOR THE TREATMENT OF MODERATE TO SEVERE PSORIASIS IN THE UNITED KINGDOM
    Betts, K. A.
    Sundaram, M.
    Mughal, F.
    Yan, S. Y.
    Signorovitch, J.
    Wang, K.
    Wu, E. Q.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A505 - A506
  • [8] Effect of Prior Biologic Use on Cost-Effectiveness of Brodalumab vs. Ustekinumab for Treatment of Moderate-to-Severe Psoriasis in the United States
    Steven R. Feldman
    Shipra Rastogi
    Jay Lin
    [J]. Dermatology and Therapy, 2018, 8 : 441 - 453
  • [9] Effect of Prior Biologic Use on Cost-Effectiveness of Brodalumab vs. Ustekinumab for Treatment of Moderate-to-Severe Psoriasis in the United States
    Feldman, Steven R.
    Rastogi, Shipra
    Lin, Jay
    [J]. DERMATOLOGY AND THERAPY, 2018, 8 (03) : 441 - 453
  • [10] COST-EFFECTIVENESS OF SEQUENCES OF BIOLOGIC TREATMENTS FOR MODERATE-TO-SEVERE PSORIASIS IN FINLAND
    Asseburg, C.
    Valgardsson, S.
    Soini, E. J.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A507 - A508
12345